[go: up one dir, main page]

PE20090371A1 - Formulacion de nevirapina de liberacion prolongada - Google Patents

Formulacion de nevirapina de liberacion prolongada

Info

Publication number
PE20090371A1
PE20090371A1 PE2008000969A PE2008000969A PE20090371A1 PE 20090371 A1 PE20090371 A1 PE 20090371A1 PE 2008000969 A PE2008000969 A PE 2008000969A PE 2008000969 A PE2008000969 A PE 2008000969A PE 20090371 A1 PE20090371 A1 PE 20090371A1
Authority
PE
Peru
Prior art keywords
composition
prolonged release
nevirapin
formulation
nevirapine
Prior art date
Application number
PE2008000969A
Other languages
English (en)
Inventor
Michael Cappola
Svetlana Sienkiewicz
Glenn Charles Snow
Feng-Jing Chen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090371(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20090371A1 publication Critical patent/PE20090371A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) NEVIRAPINA EN UNA CANTIDAD DE 300MG A 400MG; B) UNA MATRIZ DE LIBERACION PROLONGADA QUE COMPRENDE HIPROMELOSA EN UNA CANTIDAD DE 270MG O EN UN PORCENTAJE DE 20% A 25% EN PESO DE LA COMPOSICION; C) LACTOSA MONOHIDRATO EN UNA CANTIDAD DE 400MG EN LA COMPOSICION; D) ESTEARATO DE MAGNESIO EN UNA CANTIDAD DE 10MG EN LA COMPOSICION. LA FORMA DE DOSIFICACION DE LA COMPOSICION ES UNA FORMA SOLIDA TAL COMO COMPRIMIDO SIENDO UTIL EN EL TRATAMIENTO DE UNA INFECCION POR EL VIRUS DE INMUNODEFICIENCIA HUMANA TIPO 1 (VIH-1)
PE2008000969A 2007-06-08 2008-06-06 Formulacion de nevirapina de liberacion prolongada PE20090371A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94276507P 2007-06-08 2007-06-08

Publications (1)

Publication Number Publication Date
PE20090371A1 true PE20090371A1 (es) 2009-04-24

Family

ID=39739795

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008000969A PE20090371A1 (es) 2007-06-08 2008-06-06 Formulacion de nevirapina de liberacion prolongada
PE2013000070A PE20131035A1 (es) 2007-06-08 2008-06-06 Formulacion de nevirapina de liberacion prolongada

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2013000070A PE20131035A1 (es) 2007-06-08 2008-06-06 Formulacion de nevirapina de liberacion prolongada

Country Status (28)

Country Link
US (1) US8460704B2 (es)
EP (1) EP2155169B1 (es)
JP (1) JP5417662B2 (es)
KR (1) KR101017862B1 (es)
CN (1) CN101784263B (es)
AR (1) AR066924A1 (es)
AU (1) AU2008262031B2 (es)
BR (1) BRPI0811732A2 (es)
CA (1) CA2687491C (es)
CL (1) CL2008001678A1 (es)
CO (1) CO6150128A2 (es)
DK (1) DK2155169T3 (es)
EA (1) EA018377B1 (es)
EC (1) ECSP099561A (es)
ES (1) ES2574836T3 (es)
HU (1) HUE028598T2 (es)
IL (1) IL199924A0 (es)
MA (1) MA31430B1 (es)
MX (1) MX2009007764A (es)
NZ (1) NZ578664A (es)
PE (2) PE20090371A1 (es)
PL (1) PL2155169T3 (es)
TN (1) TN2009000510A1 (es)
TW (1) TWI419716B (es)
UA (1) UA97971C2 (es)
UY (1) UY31128A1 (es)
WO (1) WO2008154234A2 (es)
ZA (1) ZA200904939B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EA018377B1 (ru) 2007-06-08 2013-07-30 Бёрингер Ингельхайм Интернациональ Гмбх Препарат невирапина пролонгированного высвобождения
EP4074327A1 (en) 2008-06-27 2022-10-19 Duke University Therapeutic agents comprising elastin-like peptides
WO2012164241A1 (en) 2011-05-30 2012-12-06 Cipla Limited Pharmaceutical antiretroviral composition
WO2013028989A1 (en) * 2011-08-24 2013-02-28 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
US20150104511A1 (en) * 2012-03-05 2015-04-16 Cipla Limited Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine
CN104523630B (zh) * 2015-01-22 2017-08-25 山东新时代药业有限公司 一种奈韦拉平片剂
EP3153157A1 (en) 2015-10-09 2017-04-12 Teva Pharmaceutical Works Private Limited Company Pharmaceutical composition for prolonged release of nevirapine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) * 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2030056C (en) 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
PT1035834E (pt) * 1997-12-05 2002-09-30 Alza Corp Forma de dosagem osmotica que compreende primeiro e segundo revestimentos
CA2354472C (en) * 1998-12-17 2009-02-24 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
ES2255490T3 (es) * 1999-03-31 2006-07-01 Janssen Pharmaceutica N.V. Almidon pregelatinizado en una formulacion de liberacion controlada.
CZ300712B6 (cs) * 1999-09-24 2009-07-22 Janssen Pharmaceutica N. V. Cásticová farmaceutická kompozice, pevná disperze a farmaceutická dávková forma, zpusoby jejich prípravy a použití a obchodní balení s jejich obsahem
JP2003516345A (ja) 1999-12-09 2003-05-13 アルザ・コーポレーション 抗ウイルス剤
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
WO2002092095A1 (en) 2001-05-11 2002-11-21 Boehringer Ingelheim International Gmbh Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
WO2004043435A2 (en) 2002-11-13 2004-05-27 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
EP1643946A2 (en) 2003-06-20 2006-04-12 Viral Genomix, Inc. Compositions for and methods for treating hiv
EP1673072B1 (en) 2003-10-01 2007-04-04 Lupin Limited A controlled release pharmaceutical composition and a process for preparing the same
NZ575950A (en) 2003-11-13 2010-06-25 Psivida Inc Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
KR101284361B1 (ko) * 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
US20110104267A1 (en) * 2005-04-25 2011-05-05 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
AU2006263338A1 (en) 2005-06-29 2007-01-04 Panacea Biotec Ltd. Pharmaceutical sustained release compositions and processes thereof
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CA2625776A1 (en) 2005-10-14 2007-04-26 Microdose Technologies, Inc. Pharmaceutical packaging of an oral dosage combination
EA018377B1 (ru) 2007-06-08 2013-07-30 Бёрингер Ингельхайм Интернациональ Гмбх Препарат невирапина пролонгированного высвобождения

Also Published As

Publication number Publication date
EA018377B1 (ru) 2013-07-30
PE20131035A1 (es) 2013-10-01
HK1145806A1 (en) 2011-05-06
UA97971C2 (ru) 2012-04-10
US8460704B2 (en) 2013-06-11
ES2574836T3 (es) 2016-06-22
US20100278918A1 (en) 2010-11-04
CN101784263A (zh) 2010-07-21
JP2010520891A (ja) 2010-06-17
CL2008001678A1 (es) 2009-09-11
JP5417662B2 (ja) 2014-02-19
HUE028598T2 (en) 2016-12-28
PL2155169T3 (pl) 2016-09-30
TN2009000510A1 (en) 2011-03-31
EP2155169A2 (en) 2010-02-24
AU2008262031B2 (en) 2011-08-25
AU2008262031A1 (en) 2008-12-18
WO2008154234A9 (en) 2009-11-26
ECSP099561A (es) 2009-09-29
CA2687491A1 (en) 2008-12-18
NZ578664A (en) 2011-11-25
AR066924A1 (es) 2009-09-23
TWI419716B (zh) 2013-12-21
KR101017862B1 (ko) 2011-03-04
ZA200904939B (en) 2010-04-28
IL199924A0 (en) 2010-04-15
WO2008154234A2 (en) 2008-12-18
CN101784263B (zh) 2012-11-07
EA200900958A1 (ru) 2010-04-30
BRPI0811732A2 (pt) 2014-11-18
WO2008154234A3 (en) 2010-01-21
EP2155169B1 (en) 2016-03-23
CA2687491C (en) 2011-09-20
CO6150128A2 (es) 2010-04-20
DK2155169T3 (en) 2016-06-13
MX2009007764A (es) 2009-09-10
UY31128A1 (es) 2009-01-30
KR20100020447A (ko) 2010-02-22
TW200916127A (en) 2009-04-16
MA31430B1 (fr) 2010-06-01

Similar Documents

Publication Publication Date Title
PE20090371A1 (es) Formulacion de nevirapina de liberacion prolongada
ECSP13012473A (es) Forma de dosificación resistente a alteración que comprende un polímero aniónico
ECSP11011456A (es) Inhibidores de la replicación viral novedosos
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
CL2017002792A1 (es) Derivados de ciclohexano sustituido con amido
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
UY32260A (es) Forma de dosificación farmacéutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina ii y/o diuretico
PE20120713A1 (es) Composiciones sublinguales de dexmedetomidina y metodos para su uso
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
UA107112C2 (uk) Активатори розчинної гуанілатциклази
PE20120018A1 (es) Composicion farmaceutica de linagliptina y 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, forma farmaceutica y procedimiento para su preparacion
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
PH12016500420A1 (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
PE20080153A1 (es) Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)
CL2009000598A1 (es) Composicion farmaceutica oral que comprende particulas de liberacion pulsatil controlada en el tiempo (tpr), que contienen un farmaco poco soluble debilmente basico y un acido organico separados por una capa de liberacion sostenida, y particulas de liberacion rapida (rr); capsula que la comprende; y su uso para tratar emesis.
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
CL2009001016A1 (es) Preparacion farmaceutica solida con liberacion retardada que comprende: a) un ingrediente farmaceuticamente activo, b) 15 a 40% en peso de una mezcla de polivinilpirrolidona y/o un derivado de polivinilpirrolidona y c) al menos un diluyente.
PH12012502082A1 (en) Combination of active loaded granules with additional actives
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
MX2015008032A (es) Una composicion farmaceutica que contiene candesartan cilexetilo y amlodipina.
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
PH12018501876A1 (en) Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
CL2009000965A1 (es) Tableta oral compuesta por un compuesto i que comprende un 10 a 20% en peso de la tableta o su sal farmaceuticamente aceptable, que comprende ademas de un agente aglutinante, un desintegrante, un diluyente; proceso de preparacion de la tableta; y su uso en el tratamiento de vih y enfermedades inflamatorias.

Legal Events

Date Code Title Description
FC Refusal